Valued at USD 18.82 billion in 2025, the prostate cancer treatment market is projected to reach USD 20.83 billion in 2026 and USD 47.78 billion by 2034, growing at a CAGR of 10.9% during the forecast period 2026–2034. Active participants include AbbVie Inc., Accord Healthcare, Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Dendreon Pharmaceuticals LLC, Ferring...